Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Accumulated Expenses: 2022-2024

Historic Other Accumulated Expenses for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $753,000.

  • Stoke Therapeutics' Other Accumulated Expenses rose 33.17% to $795,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $795,000, marking a year-over-year increase of 33.17%. This contributed to the annual value of $753,000 for FY2024, which is 12.14% down from last year.
  • As of FY2024, Stoke Therapeutics' Other Accumulated Expenses stood at $753,000, which was down 12.14% from $857,000 recorded in FY2023.
  • Over the past 5 years, Stoke Therapeutics' Other Accumulated Expenses peaked at $857,000 during FY2023, and registered a low of $509,000 during FY2022.
  • Its 3-year average for Other Accumulated Expenses is $706,333, with a median of $753,000 in 2024.
  • As far as peak fluctuations go, Stoke Therapeutics' Other Accumulated Expenses spiked by 68.37% in 2023, and later dropped by 12.14% in 2024.
  • Over the past 3 years, Stoke Therapeutics' Other Accumulated Expenses (Yearly) stood at $509,000 in 2022, then spiked by 68.37% to $857,000 in 2023, then dropped by 12.14% to $753,000 in 2024.